1 3488 128 IDENTIFICATION OF DNA METHYLATION ASSOCIATED ENRICHMENT PATHWAYS IN ADULTS WITH NON-SPECIFIC CHRONIC LOW BACK PAIN. CHRONIC LOW BACK PAIN (CLBP) THAT CANNOT BE ATTRIBUTABLE TO A SPECIFIC PATHOANATOMICAL CHANGE IS ASSOCIATED WITH HIGH PERSONAL AND SOCIETAL COSTS. STILL, THE UNDERLYING MECHANISM THAT CAUSES AND SUSTAINS SUCH A PHENOTYPE IS LARGELY UNKNOWN. EMERGING EVIDENCE SUGGESTS THAT EPIGENETIC CHANGES PLAY A ROLE IN CHRONIC PAIN CONDITIONS. USING REDUCED REPRESENTATION BISULFITE SEQUENCING (RRBS), WE EVALUATED DNA METHYLATION PROFILES OF ADULTS WITH NON-SPECIFIC CLBP (N = 50) AND PAIN-FREE CONTROLS (N = 48). WE IDENTIFIED 28,325 HYPERMETHYLATED AND 36,936 HYPOMETHYLATED CPG SITES (P < 0.05). AFTER CORRECTING FOR MULTIPLE TESTING, WE IDENTIFIED 159 DMRS (Q < 0.01AND METHYLATION DIFFERENCE > 10%), THE MAJORITY OF WHICH WERE LOCATED IN CPG ISLAND (50%) AND PROMOTER REGIONS (48%) ON THE ASSOCIATED GENES. THE GENES ASSOCIATED WITH THE DIFFERENTIALLY METHYLATED REGIONS WERE HIGHLY ENRICHED IN BIOLOGICAL PROCESSES THAT HAVE PREVIOUSLY BEEN IMPLICATED IN IMMUNE SIGNALING, ENDOCHONDRAL OSSIFICATION, AND G-PROTEIN COUPLED TRANSMISSIONS. OUR FINDINGS SUPPORT INFLAMMATORY ALTERATIONS AND THE ROLE OF BONE MATURATION IN CLBP. THIS STUDY SUGGESTS THAT EPIGENETIC REGULATION HAS AN IMPORTANT ROLE IN THE PATHOPHYSIOLOGY OF NON-SPECIFIC CLBP AND A BASIS FOR FUTURE STUDIES IN BIOMARKER DEVELOPMENT AND TARGETED INTERVENTIONS. 2020 2 2634 65 EPIGENOME-WIDE DNA METHYLATION PROFILING OF CONDITIONED PAIN MODULATION IN INDIVIDUALS WITH NON-SPECIFIC CHRONIC LOW BACK PAIN. BACKGROUND: THE PATHOANATOMIC CAUSE OF CHRONIC LOW BACK PAIN (CLBP) CANNOT BE IDENTIFIED FOR UP TO 90% OF INDIVIDUALS. HOWEVER, DYSFUNCTIONAL PROCESSING OF ENDOGENOUS NOCICEPTIVE INPUT, MEASURED AS CONDITIONED PAIN MODULATION (CPM), HAS BEEN ASSOCIATED WITH CLBP AND MAY INVOLVE CHANGES IN NEURONAL GENE EXPRESSION. EPIGENETIC-INDUCED CHANGES SUCH AS DNA METHYLATION (DNAM) HAVE BEEN ASSOCIATED WITH CLBP. METHODS: IN THE PRESENT STUDY, THE RELATIONSHIP BETWEEN CPM AND DNAM CHANGES IN A SAMPLE OF COMMUNITY-DWELLING ADULTS WITH NONSPECIFIC CLBP (N = 48) AND PAIN-FREE CONTROLS (PFC; N = 50) WAS EXAMINED USING REDUCED REPRESENTATION BISULFITE SEQUENCING. GENE ONTOLOGY (GO) TERM ENRICHMENT AND KYOTO ENCYCLOPEDIA OF GENES AND GENOMES (KEGG) PATHWAY ANALYSIS WERE APPLIED TO IDENTIFY KEY PATHWAYS INVOLVED IN EFFICIENT VERSUS DEFICIENT CPM. RESULTS: BASED ON CPM EFFICIENCY, WE IDENTIFIED 6006 AND 18,305 DIFFERENTIALLY METHYLATED CPG SITES (DMCS) WITH Q VALUES < 0.01 AMONG INDIVIDUALS WITH CLBP AND PFCS, RESPECTIVELY. MOST OF THE DMCS WERE HYPOMETHYLATED AND ANNOTATED TO GENES OF RELEVANCE TO PAIN, INCLUDING OPRM1, ADRB2, CACNA2D3, GNA12, LPL, NAXD, AND ASPHD1. IN BOTH CLBP AND PFC GROUPS, THE DMCS ANNOTATED GENES ENRICHED MANY GO TERMS RELEVANT TO PAIN PROCESSING, INCLUDING TRANSCRIPTION REGULATION BY RNA POLYMERASE II, NERVOUS SYSTEM DEVELOPMENT, GENERATION OF NEURONS, NEURON DIFFERENTIATION, AND NEUROGENESIS. BOTH GROUPS ALSO ENRICHED THE PATHWAYS INVOLVED IN RAP1-SIGNALING, CANCER, AND DOPAMINERGIC NEUROGENESIS. HOWEVER, MAPK-RAS SIGNALING PATHWAYS WERE ENRICHED IN THE CLBP, NOT THE PFC GROUP. CONCLUSIONS: THIS IS THE FIRST STUDY TO INVESTIGATE THE GENOME-SCALE DNA METHYLATION PROFILES OF CPM PHENOTYPE IN ADULTS WITH CLBP AND PFCS. BASED ON CPM EFFICIENCY, FEWER DMC ENRICHMENT PATHWAYS WERE UNIQUE TO THE CLBP THAN THE PFCS GROUP. OUR RESULTS SUGGEST THAT EPIGENETICALLY INDUCED MODIFICATION OF NEURONAL DEVELOPMENT/DIFFERENTIATION PATHWAYS MAY AFFECT CPM EFFICIENCY, SUGGESTING NOVEL POTENTIAL THERAPEUTIC TARGETS FOR CENTRAL SENSITIZATION. HOWEVER, CPM EFFICIENCY AND THE EXPERIENCE OF NONSPECIFIC CLBP MAY BE INDEPENDENT. FURTHER MECHANISTIC STUDIES ARE REQUIRED TO CONFIRM THE RELATIONSHIP BETWEEN CPM, CENTRAL SENSITIZATION, AND NONSPECIFIC CLBP. 2022 3 112 31 A ROLE FOR GLOBAL DNA METHYLATION LEVEL AND IL2 EXPRESSION IN THE TRANSITION FROM ACUTE TO CHRONIC LOW BACK PAIN. OBJECTIVES: THE TRANSITION FROM ACUTE LOW BACK PAIN (ALBP) TO CHRONIC LBP (CLBP) RESULTS FROM A VARIETY OF FACTORS, INCLUDING EPIGENETIC MODIFICATIONS OF DNA. THE AIM OF THIS STUDY WAS TO (1) COMPARE GLOBAL DNA (GDNA) METHYLATION AND HISTONE ACETYLATION AT LBP ONSET BETWEEN THE ALBP AND CLBP PARTICIPANTS, (2) COMPARE MRNA EXPRESSION OF GENES WITH KNOWN ROLES IN THE TRANSDUCTION, MAINTENANCE, AND/OR MODULATION OF PAIN BETWEEN THE ALBP AND CLBP PARTICIPANTS, (3) COMPARE SOMATOSENSORY FUNCTION AND PAIN RATINGS IN OUR PARTICIPANTS, AND (4) DETERMINE IF THE AFOREMENTIONED MEASUREMENTS WERE ASSOCIATED. METHODS: A TOTAL OF 220 PARTICIPANTS WERE RECRUITED FOR THIS PROSPECTIVE OBSERVATIONAL STUDY FOLLOWING RECENT ONSET OF AN EPISODE OF LBP. WE RETAINED 45 INDIVIDUALS WHOSE GDNA WAS OF SUFFICIENT QUALITY FOR ANALYSIS. THE FINAL SAMPLE INCLUDED 14 PARTICIPANTS WHOSE PAIN RESOLVED WITHIN 6 WEEKS OF ONSET (ALBP),15 PARTICIPANTS THAT REPORTED PAIN FOR 6 MONTHS (CLBP), AND 16 HEALTHY CONTROLS. PARTICIPANTS WERE SUBJECTED TO QUANTITATIVE SENSORY TESTING (QST), BLOOD WAS DRAWN VIA VENIPUNCTURE, GDNA ISOLATED, AND GLOBAL DNA METHYLATION AND HISTONE ACETYLATION, AS WELL AS MRNA EXPRESSION OF 84 CANDIDATE GENES, WERE MEASURED. RESULTS: INDIVIDUALS THAT DEVELOP CLBP DISPLAY MULTIMODAL SOMATOSENSORY HYPERSENSITIVITY RELATIVE TO ALBP PARTICIPANTS. CLBP PARTICIPANTS ALSO HAD SIGNIFICANTLY LOWER GLOBAL DNA METHYLATION, WHICH WAS NEGATIVELY CORRELATED WITH INTERLEUKIN-2 (IL2) MRNA EXPRESSION. DISCUSSION: CLBP IS CHARACTERIZED BY SOMATOSENSORY HYPERSENSITIVITY, LOWER GLOBAL DNA METHYLATION, AND HIGHER IL2 EXPRESSION LEVEL COMPARED TO THOSE WHOSE PAIN WILL RESOLVE QUICKLY (ALBP). THESE RESULTS SUGGEST POTENTIAL DIAGNOSTIC AND THERAPEUTIC RELEVANCE FOR GLOBAL DNA METHYLATION AND IL2 EXPRESSION IN THE PATHOLOGY UNDERLYING THE TRANSITION FROM ACUTE TO CHRONIC LBP. 2021 4 1436 33 DIFFERENTIAL METHYLATION OF THE TRPA1 PROMOTER IN PAIN SENSITIVITY. CHRONIC PAIN IS A GLOBAL PUBLIC HEALTH PROBLEM, BUT THE UNDERLYING MOLECULAR MECHANISMS ARE NOT FULLY UNDERSTOOD. HERE WE EXAMINE GENOME-WIDE DNA METHYLATION, FIRST IN 50 IDENTICAL TWINS DISCORDANT FOR HEAT PAIN SENSITIVITY AND THEN IN 50 FURTHER UNRELATED INDIVIDUALS. WHOLE-BLOOD DNA METHYLATION WAS CHARACTERIZED AT 5.2 MILLION LOCI BY MEDIP SEQUENCING AND ASSESSED LONGITUDINALLY TO IDENTIFY DIFFERENTIALLY METHYLATED REGIONS ASSOCIATED WITH HIGH OR LOW PAIN SENSITIVITY (PAIN DMRS). NINE META-ANALYSIS PAIN DMRS SHOW ROBUST EVIDENCE FOR ASSOCIATION (FALSE DISCOVERY RATE 5%) WITH THE STRONGEST SIGNAL IN THE PAIN GENE TRPA1 (P=1.2 X 10(-13)). SEVERAL PAIN DMRS SHOW LONGITUDINAL STABILITY CONSISTENT WITH SUSCEPTIBILITY EFFECTS, HAVE SIMILAR METHYLATION LEVELS IN THE BRAIN AND ALTERED EXPRESSION IN THE SKIN. OUR APPROACH IDENTIFIES EPIGENETIC CHANGES IN BOTH NOVEL AND ESTABLISHED CANDIDATE GENES THAT PROVIDE MOLECULAR INSIGHTS INTO PAIN AND MAY GENERALIZE TO OTHER COMPLEX TRAITS. 2014 5 1345 40 DETECTION OF DIFFERENTIALLY METHYLATED REGIONS USING BAYES FACTOR FOR ORDINAL GROUP RESPONSES. RESEARCHERS IN GENOMICS ARE INCREASINGLY INTERESTED IN EPIGENETIC FACTORS SUCH AS DNA METHYLATION, BECAUSE THEY PLAY AN IMPORTANT ROLE IN REGULATING GENE EXPRESSION WITHOUT CHANGES IN THE DNA SEQUENCE. THERE HAVE BEEN SIGNIFICANT ADVANCES IN DEVELOPING STATISTICAL METHODS TO DETECT DIFFERENTIALLY METHYLATED REGIONS (DMRS) ASSOCIATED WITH BINARY DISEASE STATUS. MOST OF THESE METHODS ARE BEING DEVELOPED FOR DETECTING DIFFERENTIAL METHYLATION RATES BETWEEN CASES AND CONTROLS. WE CONSIDER MULTIPLE SEVERITY LEVELS OF DISEASE, AND DEVELOP A BAYESIAN STATISTICAL METHOD TO DETECT THE REGION WITH INCREASING (OR DECREASING) METHYLATION RATES AS THE DISEASE SEVERITY INCREASES. PATIENTS ARE CLASSIFIED INTO MORE THAN TWO GROUPS, BASED ON THE DISEASE SEVERITY (E.G., STAGES OF CANCER), AND DMRS ARE DETECTED BY USING MOVING WINDOWS ALONG THE GENOME. WITHIN EACH WINDOW, THE BAYES FACTOR IS CALCULATED TO TEST THE HYPOTHESIS OF MONOTONIC INCREASE IN METHYLATION RATES CORRESPONDING TO SEVERITY OF THE DISEASE VERSUS NO DIFFERENCE. A MIXED-EFFECT MODEL IS USED TO INCORPORATE THE CORRELATION OF METHYLATION RATES OF NEARBY CPG SITES IN THE REGION. RESULTS FROM EXTENSIVE SIMULATION INDICATE THAT OUR PROPOSED METHOD IS STATISTICALLY VALID AND REASONABLY POWERFUL. WE DEMONSTRATE OUR APPROACH ON A BISULFITE SEQUENCING DATASET FROM A CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) STUDY. 2019 6 1909 51 ENRICHMENT OF GENOMIC PATHWAYS BASED ON DIFFERENTIAL DNA METHYLATION PROFILES ASSOCIATED WITH CHRONIC MUSCULOSKELETAL PAIN IN OLDER ADULTS: AN EXPLORATORY STUDY. OUR STUDY AIMED TO IDENTIFY DIFFERENTIALLY METHYLATED CPGS/REGIONS AND THEIR ENRICHED GENOMIC PATHWAYS ASSOCIATED WITH UNDERLYING CHRONIC MUSCULOSKELETAL PAIN IN OLDER INDIVIDUALS. WE RECRUITED COGNITIVELY HEALTHY OLDER ADULTS WITH (N = 20) AND WITHOUT (N = 9) SELF-REPORTED MUSCULOSKELETAL PAIN AND COLLECTED DNA FROM PERIPHERAL BLOOD THAT WAS ANALYZED USING METHYLATIONEPIC ARRAYS. WE IDENTIFIED 31,739 HYPERMETHYLATED CPG AND 10,811 HYPOMETHYLATED CPG PROBES (PS